Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021
- Webinar Scheduled for
2:30 PM PT/ 5:30 PM ET
David Chang, M.D., Ph.D. – President, Chief Executive Officer and Co-Founder Rafael Amado, M.D. – Executive Vice President of Research & Development and Chief Medical Officer Eric Schmidt, Ph.D. – Chief Financial Officer Christine Cassiano– Chief Communications Officer
Frederick Locke, M.D. – Co-Leader of the Moffitt Immuno-Oncology Program and the Vice Chair and Associate Member of the Department of Blood and Marrow Transplantand Cellular Immunotherapy at the Moffitt Cancer Center Michael Tees, M.D., M.P.H. – Associate Member Physician, Colorado Blood Cancer Institute, Sarah Cannon Research Institute Lazaros Lekakis, M.D. – Associate Professor of Clinical Medicine, Transplantation and Cellular Therapy, Sylvester Cancer Center, University of Miami
Poster presentations on data included in the Forum will be presented at the 2021
Please register for the webinar on the Company's website at www.allogene.com under the Investors tab in the News and Events section (https://ir.allogene.com/events) or by clicking the following link directly.
Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. The materials presented will be available on the Allogene website.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability to present data, and the potential benefits of AlloCAR T™ therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the
AlloCAR T™ is a trademark of
Allogene’s CD19 AlloCAR T program utilizes Cellectis technologies. ALLO-501 and ALLO-501A are being jointly developed under a collaboration agreement between Servier1 and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries.
1 Servier is an independent international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes).
Allogene Media/Investor Contact:
Chief Communications Officer
Source: Allogene Therapeutics, Inc.